Cargando…

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

PURPOSE: Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase IV (DPP-IV) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This study aimed to investigate the pharmacokinetic and pharmacodynamic profiles and tolerability of evogliptin after repe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Namyi, Park, Min Kyu, Kim, Tae-Eun, Bahng, Mi Young, Lim, Kyoung Soo, Cho, Sang-Heon, Yoon, Seo Hyun, Cho, Joo-Youn, Jang, In-Jin, Yu, Kyung-Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199987/ https://www.ncbi.nlm.nih.gov/pubmed/25336915 http://dx.doi.org/10.2147/DDDT.S65678

Ejemplares similares

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice
por: Min, Hye Sook, et al.
Publicado: (2021)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis
por: Chalmers, James D., et al.
Publicado: (2022)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
por: Chae, Yu-Na, et al.
Publicado: (2015)

Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
por: Seo, Songyi, et al.
Publicado: (2020)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
por: Salles, Thiago A., et al.
Publicado: (2015)

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis
por: Larrinaga, Gorka, et al.
Publicado: (2015)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
por: Nojima, Hiroyuki, et al.
Publicado: (2016)

Constituents of Coreopsis lanceolata Flower and Their Dipeptidyl Peptidase IV Inhibitory Effects
por: Kim, Bo-Ram, et al.
Publicado: (2020)

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021)

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease
por: Zhang, Yuanyuan, et al.
Publicado: (2022)

Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV
por: Rohani, et al.
Publicado: (2023)

Structural Similarities, in Relation with the Cross-Reactivity, of Hymenoptera Allergenic Dipeptidyl Peptidases IV—An Overall Comparison Including a New Dipeptidyl Peptidase IV Sequence from Vespa velutina
por: Monsalve, Rafael I., et al.
Publicado: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men
por: Tsuchiya, Saori, et al.
Publicado: (2016)

Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020)

A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study
por: Chung, Hyewon, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
por: Shin, Dongseong, et al.
Publicado: (2017)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
por: Cho, Pyung Goo, et al.
Publicado: (2023)

A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells
por: Wesley, Umadevi V., et al.
Publicado: (1999)

Dipeptidyl Peptidase IV and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) study
por: Luft, Vivian C., et al.
Publicado: (2010)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
por: Joo, Kwon Wook, et al.
Publicado: (2013)

Endogenous dipeptidyl peptidase IV modulates skeletal muscle arteriolar diameter in rats
por: Neidert, Leslie E., et al.
Publicado: (2018)

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review
por: Liu, Rui, et al.
Publicado: (2019)

Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
por: Rozano, Lina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vbm3p0mg81h431rpst09t71vt7